IAM — Iambic Therapeutics, Inc.

IAM

HOLD / NEUTRALNeutral

Composite

46.30

Technical

34.40

Fundamental

54.30

Rank

—

Price

16.01

Hurst

—

As of

Oct 21, 2026

Daily

Iambic Therapeutics, Inc.

HealthcareBiotechnology

Iambic Therapeutics is a biotechnology firm that uses artificial intelligence to discover and optimize drug candidates targeting various proteins and cellular pathways. The company's pipeline includes selective inhibitors for HER2, KIF18A, and CDK2/4, along with proprietary computational platforms designed to accelerate small molecule drug development. Based in San Diego and incorporated in 2019, the company operates across multiple markets globally.

Market cap

$758.9M

P/E (trailing)

—

P/E (forward)

—

PEG ratio

—

Dividend yield

0.00%

Beta

—

52w range

14.10 – 25.00

Return on equity

—

Profit margin

0.00%

Revenue growth

+224.70%

Earnings growth

—

Price history

1Y: 15.15 (-19.9%) · range 15.15–23.81

Cycle position

24/ 100 cycle scoreENTRY ZONE

ENTRYAPPROACHMID-BULLNEAR-TOPEXIT

entry readiness 59 · MODERATE · exit proximity 0

Conviction

44/ 100 · maturity 29%

VScore.1619

Buildup.2830

EMA entry setup.3559

Fundamentals.2154

Contributing sources

Source	Score	Last seen
insider-activity	0.400	Oct 21, 2026

Pattern & cluster

Pattern

none

Cluster

NEUTRAL

Forward returns

Not yet labeled — the study prices these as positions mature.